110 related articles for article (PubMed ID: 2150330)
1. C127 cells resistant to transformation by tyrosine protein kinase oncogenes.
Cuadrado A; Talbot N; Barbacid M
Cell Growth Differ; 1990 Jan; 1(1):9-15. PubMed ID: 2150330
[TBL] [Abstract][Full Text] [Related]
2. Transformation by Raf and other oncogenes renders cells differentially sensitive to growth inhibition by a dominant negative c-jun mutant.
Rapp UR; Troppmair J; Beck T; Birrer MJ
Oncogene; 1994 Dec; 9(12):3493-8. PubMed ID: 7970709
[TBL] [Abstract][Full Text] [Related]
3. Transformation-resistant mos revertant is unable to activate MAP kinase kinase in response to v-mos or v-raf.
Topol LZ; Marx M; Calothy G; Blair DG
Cell Growth Differ; 1995 Jan; 6(1):27-38. PubMed ID: 7718484
[TBL] [Abstract][Full Text] [Related]
4. K252a is a selective inhibitor of the tyrosine protein kinase activity of the trk family of oncogenes and neurotrophin receptors.
Tapley P; Lamballe F; Barbacid M
Oncogene; 1992 Feb; 7(2):371-81. PubMed ID: 1312698
[TBL] [Abstract][Full Text] [Related]
5. Raf revertant cells resist transformation by non-nuclear oncogenes and are deficient in the induction of early response genes by TPA and serum.
Kolch W; Heidecker G; Troppmair J; Yanagihara K; Bassin RH; Rapp UR
Oncogene; 1993 Feb; 8(2):361-70. PubMed ID: 8426742
[TBL] [Abstract][Full Text] [Related]
6. Suppression of v-Src transformation in primary rat embryo fibroblasts.
Inoue H; Tavoloni N; Hanafusa H
Oncogene; 1995 Jul; 11(2):231-8. PubMed ID: 7624140
[TBL] [Abstract][Full Text] [Related]
7. Most of the substrates of oncogenic viral tyrosine protein kinases can be phosphorylated by cellular tyrosine protein kinases in normal cells.
Kamps MP; Sefton BM
Oncogene Res; 1988 Sep; 3(2):105-15. PubMed ID: 2465525
[TBL] [Abstract][Full Text] [Related]
8. SCH 51344 inhibits ras transformation by a novel mechanism.
Kumar CC; Prorock-Rogers C; Kelly J; Dong Z; Lin JJ; Armstrong L; Kung HF; Weber MJ; Afonso A
Cancer Res; 1995 Nov; 55(21):5106-17. PubMed ID: 7585559
[TBL] [Abstract][Full Text] [Related]
9. trans-Dominant suppressor mutations of the H-ras oncogene.
Ogiso Y; Gutierrez L; Wrathall LS; Lu YY; Blair DG; Clanton DJ; Hwang YW; Shih TY
Cell Growth Differ; 1990 May; 1(5):217-24. PubMed ID: 2150753
[TBL] [Abstract][Full Text] [Related]
10. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
Rusyn EV; Reynolds ER; Shao H; Grana TM; Chan TO; Andres DA; Cox AD
Oncogene; 2000 Sep; 19(41):4685-94. PubMed ID: 11032018
[TBL] [Abstract][Full Text] [Related]
11. A dominant suppressive mutation in a cellular gene restores the nontransformed phenotype to v-fms-transformed mink cells.
Kato J; Sherr CJ
Oncogene; 1991 May; 6(5):687-93. PubMed ID: 2052353
[TBL] [Abstract][Full Text] [Related]
12. The fms gene and the CSF-1 receptor.
Sherr CJ; Rettenmier CW
Cancer Surv; 1986; 5(2):221-32. PubMed ID: 3022923
[TBL] [Abstract][Full Text] [Related]
13. Isolation of a new class of 'flat' revertants from ras-transformed NIH3T3 cells using cis-4-hydroxy-L-proline.
Yanagihara K; Ciardiello F; Talbot N; McGeady ML; Cooper H; Benade L; Salomon DS; Bassin RH
Oncogene; 1990 Aug; 5(8):1179-86. PubMed ID: 2202950
[TBL] [Abstract][Full Text] [Related]
14. A role for Ras in v-Crk transformation.
Greulich H; Hanafusa H
Cell Growth Differ; 1996 Nov; 7(11):1443-51. PubMed ID: 8930393
[TBL] [Abstract][Full Text] [Related]
15. Properties of tripartite chimeras between Src and Lck.
Kashishian A; MacAuley A; Cooper JA
Oncogene; 1990 Oct; 5(10):1463-70. PubMed ID: 2250908
[TBL] [Abstract][Full Text] [Related]
16. The ETV6-NTRK3 gene fusion encodes a chimeric protein tyrosine kinase that transforms NIH3T3 cells.
Wai DH; Knezevich SR; Lucas T; Jansen B; Kay RJ; Sorensen PH
Oncogene; 2000 Feb; 19(7):906-15. PubMed ID: 10702799
[TBL] [Abstract][Full Text] [Related]
17. Resistance of NIH3T3 cells to v-fes transformation induced by a dominant negative H-ras mutant.
Ogiso Y; Yokoyama T; Watari H; Shih TY; Kuzumaki N
Exp Cell Res; 1993 Oct; 208(2):415-21. PubMed ID: 7690710
[TBL] [Abstract][Full Text] [Related]
18. The trk oncogene abrogates growth factor requirements and transforms hematopoietic cells.
Katzav S; Martin-Zanca D; Barbacid M; Hedge AM; Isfort R; Ihle JN
Oncogene; 1989 Sep; 4(9):1129-35. PubMed ID: 2674855
[TBL] [Abstract][Full Text] [Related]
19. An intact PDGF signaling pathway is required for efficient growth transformation of mouse C127 cells by the bovine papillomavirus E5 protein.
Riese DJ; DiMaio D
Oncogene; 1995 Apr; 10(7):1431-9. PubMed ID: 7731695
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic activation of the tyrosine kinase domain of the human trk proto-oncogene by fusion to a cell adhesion molecule.
Albor A; Thraves PJ; Dritschilo A; Notario V
Oncogene; 1996 Oct; 13(8):1755-63. PubMed ID: 8895522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
